Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction—1-year follow-up results of the COMPARE CRUSH trial

Rosanne F. Vogel, Ronak Delewi, Jeroen M. Wilschut, Miguel E. Lemmert, Roberto Diletti, Ria van Vliet, Nancy W.P.L. van der Waarden, Rutger Jan Nuis, Valeria Paradies, Dimitrios Alexopoulos, Felix Zijlstra, Gilles Montalescot, Dominick J. Angiolillo, Mitchell W. Krucoff, Pieter C. Smits, Nicolas M. Van Mieghem, Georgios J. Vlachojannis*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The present research letter reports the 1-year clinical outcomes of the randomized COMPARE CRUSH trial, which allocated STEMI patients at first medical contact in the ambulance to receive either crushed or integral tablets of prasugrel loading dose. This trial aimed to investigate whether early enhanced antiplatelet effect constituted by the crushed potent oral P2Y12 inhibitor prasugrel could lead to improved early myocardial reperfusion and clinical outcomes.

Original languageEnglish
Pages (from-to)26-30
Number of pages5
JournalAmerican Heart Journal
Volume252
DOIs
Publication statusPublished - Oct 2022

Bibliographical note

Funding Information:
The COMPARE CRUSH trial was funded by grants from MicroPort and Daiichi-Sankyo. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents.

Funding Information:
The COMPARE CRUSH trial was funded by Maasstad research B.V. (Rotterdam, the Netherlands), which received unrestricted grants from Daiichi-Sankyo (grant number 039-20170327-EFI ) and Shanghai MicroPort Medical (grant number MPSH20170801148570110945). The funding companies were not involved in the conduct of the trial, the analysis of the data, or the drafts of the manuscripts.

Funding Information:
Dr. Angiolillo declares that he has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, and Sanofi. D.J.A. also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. Prof. Dr. D. Alexopoulos declares that he has received consulting fees or honoraria from AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Chiesi Hellas, Medtronic and Pfizer. Prof. Dr. G. Montalescot reports research or educational Grants to the Institution or Consulting/Lecture Fees from Abbott, Amgen, Astrazeneca, Bayer, Boeringer Ingelheim, Boston-Scientific, Bristol-Myers Squibb, Cell-Prothera, Europa, IRIS-Servier, Novartis, Medtronic, MSD, Pfizer, Quantum Genomics, Sanofi-Aventis. Prof. Dr. Van Mieghem has received institutional research grant support from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Medtronic, Teleflex, PulseCath BV and Daiichi-Sankyo. Dr. Smits declares that he has received research grants from Daiichi Sankyo and Shanghai MicroPort. Dr. Vlachojannis has received consulting fees from AstraZeneca, and research grants from Daiichi Sankyo and Shanghai MicroPort. Other authors have nothing to disclose.

Publisher Copyright:
© 2022 Elsevier Inc.

Fingerprint

Dive into the research topics of 'Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction—1-year follow-up results of the COMPARE CRUSH trial'. Together they form a unique fingerprint.

Cite this